Lumify for Glaucoma Side Effects
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing Lumify™ eye drops, which help reduce eye redness, in glaucoma patients who are already using Brimonidine eye drops. These patients often have red eyes as a side effect of their current treatment. Lumify™ works by making the blood vessels in the eyes smaller, which helps to reduce redness.
Who Is on the Research Team?
Ze Zhang, MD
Principal Investigator
Tulane University
Are You a Good Fit for This Trial?
This trial is for adults over 18 with primary open-angle glaucoma who've been using Brimonidine eye drops (0.1%, 0.15%, or 0.2%) for more than six weeks and can consent to participate. It's not for pregnant individuals, prisoners, those with recent surgeries, lid surgery or botox history, allergies to brimonidine, or use of certain eye medications within the last week.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single drop of either Lumify™ or a sterile balanced saline solution in each eye
Follow-up
Participants are monitored for ocular redness, intraocular pressure, and eyelid position 60 minutes after application
What Are the Treatments Tested in This Trial?
Interventions
- Brimonidine Tartrate Ophthalmic Solution 0.025%
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tulane University
Lead Sponsor